Project My Heart Your Heart: Pacemaker Reuse
Launched by UNIVERSITY OF MICHIGAN · Jul 8, 2019
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Life expectancy ≥ 2 years.
- • Indications for device implantation must be fulfilled per standard of care. Consistent with 2008 American College of Cardiology / American Heart Association guidelines for device therapy, one of the following class I indications must be met.
- • Sinus Node Dysfunction
- • Acquired Atrioventricular (AV) Block
- • Chronic Bifascicular Block
- • Hypersensitive Carotid Syndrome
- • Lack of financial ability to pay for a new device must be assessed and documented.
- • All other methods of new device acquisition must be exhausted.
- • Patient must be agreeable and able to follow-up with the implanting center within 2 weeks for wound check, at 2 months, 6 months, and every 6 months thereafter for routine pacemaker checks.
- Exclusion Criteria:
- • Severe valvular disease
- • Severe pulmonary disease
- • End-stage renal disease (creatinine clearance \< 30 mL/min) whether or not on dialysis
- • Evidence of ongoing systemic infection
- • Prior pacemaker or implantable cardioverter-defibrillator implantation
- • Significant contraindication to pacemaker implantation per evaluation of the implanting physician (very high risk of complications).
- • Presence of any other condition that the local investigator feels would be problematic or would restrict or limit the participation of the patient for the entire study period
- • Pregnant women
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Eldoret, , Kenya
Freetown, , Sierra Leone
Barquisimeto, Lara, Venezuela
Ikeja, Lagos, Nigeria
Port Harcourt, Rivers, Nigeria
Asunción, , Paraguay
Monterrey, , Mexico
Maputo, , Mozambique
Patients applied
Trial Officials
Thomas Crawford, MD
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials